BawejaR, FaraoneSV, ChildressAC, et al.From consensus statement to pills to pixels: New innovations in attention-deficit/hyperactivity disorder care. J Child Adolesc Psychopharmacol, 2024; 34(4):167–182; doi: 10.1089/cap.2024.0022
2.
BerloffaS, MasiG, FalconeF, et al.Clozapine treatment for aggressive behaviors in youths with neurodevelopmental disorders. J Child Adolesc Psychopharmacol, 2024; 34(3):148–156; doi: 10.1089/cap.2023.0097
3.
DinnissenM, DietrichA, BierensM, et al.Long-term effectiveness of off-label risperidone treatment in children and adolescents: A Randomized, Placebo-Controlled Discontinuation Study. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2023.0065
4.
HarrisC, SumyMSA, FeyginYB, et al.Changes in psychiatric medication use during the COVID-19 Pandemic in a pediatric long-term care facility. J Child Adolesc Psychopharmacol, 2024; 34(4):210–213; doi: 10.1089/cap.2023.0067
5.
LkamelK, AssermouhJ. Exploring the relationship between smartphone addiction, psychological distress, stress, and self-esteem among moroccan high school students: A Regression Equation Modeling Study. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2024.0029
6.
NaguyA, PridmoreS, AlamiriB. Paradoxical sedation on methylphenidate in a child with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2024.0031
7.
StrawnJR, GeraciotiTD. Editorial: A better perspective on antipsychotic-related hyperprolactinemia in children and adolescents. J Am Acad Child Adolesc Psychiatry, 2023; 62(9):967–969; doi: 10.1016/j.jaac.2023.05.003
8.
Tebbett-MockAA, SaitoE, TangSX, et al.The mental health toll of the COVID-19 pandemic on adolescents receiving inpatient psychiatric treatment. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2024.0020
9.
Valicenti-McDermottM, RivelisE, SeijoR, et al.Diagnosis of autism in school age and adolescence in an ethnically diverse population. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2024.0004
10.
ZhangY, ZhangW, YuE. Systematic review and meta-analysis: Pharmacological and nonpharmacological interventions for disruptive mood dysregulation disorder. J Child Adolesc Psychopharmacol, 2024; 34(5):217–225; doi: 10.1089/cap.2024.0013
